CFDE Data Portal | Search CRYBG1

	Label	Description
	CRYBG1 Gene (Entity type)	ENSG00000112297 - crystallin beta-gamma domain containing 1
	GSE233679 14 V 13 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE186471 1 V 2 CARNOSOL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE125211 0 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS

CRYBG1

ENSG00000112297 - crystallin beta-gamma domain containing 1

GSE233679 14 V 13 NICOTINAMIDE HUMAN DN

A Gene Set from LINCS

GSE240439 decitabine 1 v 2 human up

A Gene Set from LINCS

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE186471 1 V 2 CARNOSOL HUMAN DN

A Gene Set from LINCS

GSE125211 0 V 1 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

A Gene Set from LINCS

GSE48812 sulforaphane 4 v 10 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.